ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
A Randomized, Open-label, Multi-center, Phase II/III Study on Treatment With ABR-217620/Naptumomab Estafenatox Combined With IFN-alpha vs. IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Pleven, Bulgarien, 5800
- Department of Chemotherapy, University General Hospital for Active Treatment "Georgi Stranski"
-
Plovdiv, Bulgarien, 4004
- 1st Internal Department District Dispensary for Cancer Diseases with Inpatient Hospital
-
Sofia, Bulgarien, 1431
- Multifile Hospital "Aleksandrovska", Urology Clinic, Department of Oncourology
-
Sofia, Bulgarien, 1527
- Oncology Clinic, University General Hospital for Active Treatment "Tzaritza Yoanna"
-
Varna, Bulgarien, 9002
- Urology Clinic, General Hospital for Active Treatment "St. Anna"
-
Veliko Tarnovo, Bulgarien, 5000
- Department of Chemotherapy, Inter-district Dispensary for Cancer Diseases with Inpatient Hospital
-
-
-
-
-
Arkhangelsk, Den Russiske Føderation
- Arkhangelsk Regional Oncology Center
-
Chelyabinsk, Den Russiske Føderation, 454087
- Chelyabinsk Regional Oncology Center
-
Kazan, Den Russiske Føderation, 420029
- Republican Clinical Oncology Center
-
Kazan, Den Russiske Føderation, 420111
- Kazan City Oncology Center
-
Moscow, Den Russiske Føderation, 115478
- Russian Oncological Research Center n.a. N.N. Blokhin
-
Moscow, Den Russiske Føderation, 105425
- Research Institute of Urology
-
Moscow, Den Russiske Føderation, 117997
- Russian Research Center of Radiology
-
Obninsk, Den Russiske Føderation, 249036
- Medical Radiology Research Center
-
Orenburg, Den Russiske Føderation, 460021
- Orenburg Regional Clinical Oncology Center
-
St. Petersburg, Den Russiske Føderation, 191104
- Leningrad Regional Oncological Center
-
St. Petersburg, Den Russiske Føderation, 193312
- Municipal Aleksandrovskaya Hospital
-
St. Petersburg, Den Russiske Føderation, 194354
- Municipal Multi-Speciality Hospital #2
-
St. Petersburg, Den Russiske Føderation, 196247
- Municipal Hospital #26
-
St. Petersburg, Den Russiske Føderation, 197022
- Municipal Clinical Oncology Center
-
St. Petersburg, Den Russiske Føderation, 197758
- Central Research Institute of Roentgenology and Radiology
-
St. Petersburg, Den Russiske Føderation, 197758
- Research Institute of Oncology n.a. Professor N.N. Petrov
-
St. Petersburg, Den Russiske Føderation, 198205
- Municipal Hospital #15
-
Stavropol, Den Russiske Føderation, 355047
- Stavropol Territorial Clinical Oncology Center
-
Yaroslavl, Den Russiske Føderation, 150054
- Regional Clinical Oncology Hospital
-
-
-
-
-
Cambridge, Det Forenede Kongerige, CB2 0QQ
- Addenbrooke's Hospital, Cambridge Clinical Trials Centre
-
Derby, Det Forenede Kongerige, DE1 2QY
- Derby Hospital NHS Trust
-
Glasgow, Det Forenede Kongerige, G12 0YN
- The Beatson West of Scotland Cancer Centre
-
Leeds, Det Forenede Kongerige, LS9 7TF
- St. James's Institute of Oncology
-
London, Det Forenede Kongerige, SW6 6JJ
- The Royal Marsden NHS Trust
-
Manchester, Det Forenede Kongerige, M20 4BX
- The Christie Hospital NHS Trust
-
Swansea, Det Forenede Kongerige, SA2 8QA
- South Wales Cancer Institute, Singleton Hospital
-
-
-
-
-
Bucharest, Rumænien, 022328
- Fundeni Clinical Institute - Urology Department
-
Bucharest, Rumænien, 041345
- Dinu Uromedica
-
Bucharest, Rumænien, 050659
- "Prof. Dr. Th. Burghele" Clinical Hospital, Urology Clinic
-
Cluj Napoca, Rumænien, 400015
- "I. Chiricuta" Institute of Oncology
-
Cluj Napoca, Rumænien, 400016
- E-URO Medical Center
-
Constanta, Rumænien, 900635
- Provita Center SRL
-
Sibiu, Rumænien, 550245
- Sibiu Clinical Country Hospital - Urology Clinic
-
Timisoara, Rumænien, 300239
- Oncomed SRL
-
-
-
-
-
Cherkassy, Ukraine, 18009
- Cherkassy Regional Oncology Center
-
Chernigov, Ukraine, 14029
- Chernigov Regional Oncology Center
-
Dnepropetrovsk, Ukraine, 49005
- Urology Department, Dnepropetrovsk State Medical Academy
-
Dnepropetrovsk, Ukraine, 49102
- City General Hospital #4
-
Donetsk, Ukraine, 83092
- Donetsk Regional Antitumor Center
-
Ivano-Frankovsk, Ukraine, 76000
- Ivano-Frankovsk Regional Oncology Center
-
Kharkiv, Ukraine, 61037
- Kharkiv Regional Urology and Nephrology Center
-
Kiev, Ukraine, 04053
- Institute of Urology under the Academy of Medical Sciences of Ukraine, Department of Plastic and Supportive Urology
-
Kiev, Ukraine, 04053
- Institute of Urology under the Academy of Medical Sciences of Ukraine, Urology Department
-
Lvov, Ukraine, 79031
- State Regional Diagnostics and Treatment Oncology Center
-
Uzhorod, Ukraine, 88014
- Regional Oncology Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed RCC (clear cell and papillary types)
- Metastatic or inoperable locally advanced RCC
- Eligible for therapy with IFN-alpha.
- Measurable disease defined by at least 1 measurable lesion on CT scan (lesion diameter greater than or equal to 2.0 cm by a standard CT scanner or greater than or equal to 1.0 cm by a spiral CT scanner)
- Favorable or moderate risk group prognosis by MSKCC (Motzer) criteria (score 0-2)
- Karnofsky performance status greater than or equal to 70
- Age greater than or equal to 18
- Life expectancy greater than 3 months
Baseline blood counts:
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
- Platelets greater than or equal to 100 x 10^9/L
- Haemoglobin greater than or equal to 100 g/L
Baseline blood chemistry levels:
- Creatinine less than or equal to 1.5 x upper limit of normal (ULN)
- Bilirubin less than or equal to 2 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN. AST and ALT allowed less than or equal to 5 x ULN for patients with liver metastases.
- If fertile, patient will use effective method of contraception throughout the study
- Willing and able to comply with the treatment and follow-up visits and examinations
- Capable of understanding the parameters in the protocol and able to sign a written consent form
Exclusion Criteria:
- Pregnant or breastfeeding women
- Serious uncontrolled medical disorder or active infection ongoing or resolved within 2 weeks before first dose of study drug and that the investigator believes would impair the patient's ability to receive study drug
- History of malignancy within 5 years or concurrent malignancy, except successfully treated non-melanoma skin cancer, cervical cancer in situ, ductal carcinoma in situ or lobular carcinoma in situ of breast may be included
- History and/or signs of parenchymal brain metastases
- Significant cardiac disease including: history (within 6 months) or current unstable angina pectoris, congestive heart failure (NYHA stage III-IV), myocardial infarction within 12 months, or uncontrolled arterial hypertension.
- History of stroke within 5 years and/or transient ischemic attack within 6 months.
- Acute illness or evidence of infection, including unexplained fever (>100.5ºF or 38.1ºC) within 2 weeks before start of treatment
- Treatment with biological response modifiers within 3 weeks prior to the start of treatment and up to the End-of-Study visit
- Treatment with beta-blockers, including topical therapy for glaucoma, within 5 days before start of treatment and during the 4-day ABR-217620/naptumomab estafenatox treatment
- Treatment with systemic corticosteroids within 2 weeks before start of treatment or likely need for such treatment during the study
- Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis
- Known positive serology for HIV
- Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known virus carrying; patients who recovered from Hepatitis A are allowed
- Treatment with anticoagulants within 2 weeks before start of treatment, except when used to maintain the patency of a central or peripheral venous line
- Radiotherapy less than 4 weeks before start of treatment
- Major surgery or tumor embolization less than 4 weeks before start of treatment
- Previous exposure to murine monoclonal antibodies or known hypersensitivity to murine proteins
- Currently on renal dialysis treatment
- Known allergy or hypersensitivity to aminoglycosides and kanamycin
- Previous systemic anti-tumor therapy for RCC (including immunotherapy with IFN-alpha or IL-2 or any chemotherapy) except sunitinib or other oral antiangiogenic therapy
- Participation in any study with investigational drugs for RCC within 6 weeks
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: 1
|
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Andre navne:
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Andre navne:
|
|
Eksperimentel: Safety group
6-12 patients
|
10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
Andre navne:
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Andre navne:
|
|
Andet: 2
Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
|
3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time to death
Tidsramme: every 12 weeks, including after a maximum of 18 months of study treatment
|
every 12 weeks, including after a maximum of 18 months of study treatment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Progression-free survival time
Tidsramme: every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period
|
every 12 weeks for the 18-month treatment period and also every 12 weeks after the treatment period
|
|
Objective tumor response rate
Tidsramme: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Best overall response
Tidsramme: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Duration of response
Tidsramme: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Changes in sum of target lesions
Tidsramme: every 12 weeks for the 18-month treatment period
|
every 12 weeks for the 18-month treatment period
|
|
Immunological response in patients on combined treatment of ABR-217620/naptumomab estafenatox and IFN-alpha
Tidsramme: Weeks 1, 9, 17, 25, 73
|
Weeks 1, 9, 17, 25, 73
|
|
Vital signs
Tidsramme: every visit through Week 25, plus Week 73
|
every visit through Week 25, plus Week 73
|
|
Physical measurements
Tidsramme: Weeks 1, 9, 17, 25, 73
|
Weeks 1, 9, 17, 25, 73
|
|
Adverse events
Tidsramme: every visit through Week 73
|
every visit through Week 73
|
|
Laboratory safety assessments
Tidsramme: Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73
|
Weeks 1, 2, 3, 5, 9, 10, 13, 17, 18, 21, 25, and 73
|
|
Pharmacokinetic parameters of ABR-217620/naptumomab estafenatox
Tidsramme: Weeks 1, 9, and 17
|
Weeks 1, 9, and 17
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Thore Nederman, PhD, Active Biotech AB
Publikationer og nyttige links
Generelle publikationer
- Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle O, Eisen T. A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNalpha versus IFNalpha in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clin Cancer Res. 2016 Jul 1;22(13):3172-81. doi: 10.1158/1078-0432.CCR-15-0580. Epub 2016 Feb 5.
- Eisen T, Hedlund G, Forsberg G, Nordle Ö, Hawkins R. Baseline biomarker trend analysis of a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α vs IFN-α in advanced renal cell carcinoma. European Cancer Congress (ECCO) 2013; Abstract ID: 2710.
- Elkord E, Burt DJ, Sundstedt A, Nordle O, Hedlund G, Hawkins RE. Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-alpha versus IFN-alpha. Oncotarget. 2015 Feb 28;6(6):4428-39. doi: 10.18632/oncotarget.2922.
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Urologiske neoplasmer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Nyresygdomme
- Urologiske sygdomme
- Adenocarcinom
- Neoplasmer, kirtel og epitel
- Nyre-neoplasmer
- Karcinom, nyrecelle
- Karcinom
- Lægemidlers fysiologiske virkninger
- Immunologiske faktorer
- Antistoffer, monoklonale
- Immunkonjugater
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 06762004
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .